Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Leerink Partners
Biotech
Why other Big Pharmas could follow Lilly into psychedelics
Industry experts told Fierce that Eli Lilly's $2.8 billion acquisition of AtaiBeckley should give the psychedelics space added momentum.
Will Maddox
,
Darren Incorvaia
Jul 20, 2026 4:00am
Fierce Pharma
Vaccine makers facing increased volatility, uncertainty at FDA
Feb 13, 2026 11:12am
Cardiometabolic field drives M&A while cancer deals drop: report
Oct 27, 2025 2:39pm
J&J, Bayer, Santa Ana, Regenxbio and more—Chutes & Ladders
Jun 14, 2024 8:30am
